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EDITORIAL COMMENT
Intra-Aortic Balloon
Counterpulsation in Acute
Myocardial Infarction:
Too Few or Too Many?*
Reginald Low, MD, FACC
Sacramento, California
The concept of counterpulsation was introduced over four
decades ago by Clauss et al. (1) and adapted to intra-aortic
balloon pumping (IABP) by Moulopaulus et al. (2) in 1962,
and it remains the most common mode of cardiac assist.
Intra-aortic balloon counterpulsation (IABCP) was first
introduced into clinical practice by Kantrowitz et al. (3) in
1968 for the treatment of cardiogenic shock. Initially, the
12F to 14F intra-aortic balloon (IAB) catheter required
surgical insertion via a dacron graft sutured to the femoral
artery. In 1979, the IAB was adapted for percutaneous
insertion by Bregman and Casarella (4), and this was
followed in the early 1980s by a dual-lumen, wire-guided,
smaller catheter device which could be placed in 5 min with
significantly improved insertion success and reduced vascu-
lar complications (5–8). Refinements have reduced the
catheter size to 8F and 9F for 30- to 50-cc balloons, and
technically advanced consoles can rapidly shuttle the helium
gas with automatic timing.
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The physiologic principle of counterpulsation is a rapid
decrease in intra-aortic pressure synchronized to left ven-
tricular ejection followed by a rapid increase in intra-aortic
pressure during left ventricular isovolumic relaxation. Im-
pedance to left ventricular ejection is reduced (systolic
unloading), decreasing afterload, and diastolic pressure is
increased (diastolic augmentation) which improves coronary
perfusion pressure. Cardiac work is therefore reduced and
myocardial oxygen demand is decreased with concomitant
increase in myocardial oxygen supply. These physiologic
effects may be especially beneficial in patients with acute
myocardial infarction (AMI) and cardiogenic shock.
Intra-aortic balloon counterpulsation was initially used
for the treatment of patients with cardiogenic shock and left
ventricular pump failure (9). However, despite improve-
ments in hemodynamics, with increased cardiac output,
decreased pulmonary capillary wedge pressure, improved
arterial pressure, and improved urine output, results of
IABCP alone in cardiogenic shock were disappointing
(10,11). Subsequent studies of patients with cardiogenic
shock supported with IABP, followed by early angiography
and myocardial revascularization, when feasible, showed
improved survival (12). Patients with AMI and cardiogenic
shock treated with thrombolytics and IABP also appeared
to have improved outcomes (13). Additionally, patients with
mechanical complications of AMI (ventricular septal defect
and acute severe mitral regurgitation) and patients with
refractory unstable angina undergoing revascularization had
clear benefit (14,15).
The indications for IABCP in AMI expanded to include
support of severely ill patients during acute cardiac cathe-
terization and myocardial revascularization both percutane-
ous and surgical (16). Intra-aortic balloon counterpulsation
is also used to support patients with unstable angina and
depressed cardiac function undergoing cardiac surgery dur-
ing induction as well as weaning from cardiopulmonary
bypass after myocardial infarction.
In this issue of the Journal, Stone et al. (17) present
registry data on the utilization and outcomes of IABCP in
AMI. Importantly, this is a very large database that provides
valuable insight into IAB use in AMI patients while
recognizing the limitations of a registry study. The Amer-
ican College of Cardiology/American Heart Association
Task Force class 1 indications of IABP in AMI (cardiogenic
shock, mechanical complications of AMI, intractable he-
modynamically unstable ventricular arrhythmias, and refrac-
tory post myocardial infarction angina) account for about
half the use of IABP in this registry, and support for
cardiogenic shock is appropriately most common. Surpris-
ingly, support for high-risk catheterization and angioplasty
is nearly as frequent (27.3 vs. 27.2%, respectively). The need
for this type of support should be reduced with the use of a
new generation of non-ionic, low osmolar, X-ray contrast
agents, which have reduced hemodynamic and ischemic
changes during angiography. In addition, technical advances
in guide wires, balloons, stents, and pharmacologics, plus
increasing expertise in the intervention of the complex
coronary lesions significantly reduces the need for mechan-
ical assistance in the treatment of patients with AMI.
Perhaps the reassurance of mechanical hemodynamic sup-
port influences the more frequent the use of IABP in this
setting.
The hemodynamic effects of IABCP are generally depen-
dent on the patient subset with those in greatest need
(cardiogenic shock) having the most benefit, whereas the
subset with stable hemodynamics has little change because
of autoregulation. Use of IABCP in shock patients should
certainly be complemented with complete hemodynamic mon-
itoring to optimize fluid and pharmacologic management.
The serious complication rate of IABP use (severe access
site bleeding, major limb ischemia, amputation, vascular
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surgery, organ infarction, and IABP-induced mortality) in
this registry is extremely low. Anticoagulation, small cath-
eter size, guide wire insertion, and judicious use in patients
with peripheral vascular disease are likely contributors to
these good results. Pre-insertion abdominal and iliofemoral
angiography is often performed to assess feasibility of
insertion and to select insertion site, which also minimizes
complications. Unfortunately, the registry does not reflect
the frequency of patients who had indications for IABCP
but had contraindications to insertion.
In this registry, the high revascularization rates in patients
treated with IABP are consistent with current practice of
AMI patient care and improved outcomes of specific patient
subsets such as those with shock. The ability to revascularize
acutely ill patients with AMI quickly and safely contributes
to this approach in patient care.
Essential to the care of patients with AMI is the timely
diagnosis and early treatment with an appropriate reperfu-
sion strategy. The astute clinician with the aid of electro-
cardiographic, hemodynamic, and echocardiographic infor-
mation can quickly identify the high-risk and cardiogenic
shock patients who may benefit from IABCP support.
Despite the recognized benefit of mechanical support in
AMI shock, IABP was placed in only 22% (68 of 310
patients) of AMI shock patients in the Global Utilization of
Streptokinase and Tissue Plasminogen Activator for Oc-
cluded Coronary Arteries (GUSTO I) study, reported by
Anderson et al. (18). Alternatively, in high-risk patients
with AMI treated with primary angioplasty in a randomized
study, IABP use prophylactically did not reduce infarct-
related artery reocclusion or reinfarction, nor did it promote
recovery or improve clinical outcomes (19). The use of
IABP support for angiography and intervention in the
“high-risk” AMI patient may offer benefit not easily mea-
sured or detected, such as less hypotension, ischemic elec-
trocardiogram changes, and pain during the procedure for
the patient and reduced stress for the interventionalist and
cardiac catheterization laboratory staff. Important issues
such as duration of IABCP support in cardiogenic shock to
optimize recovery of cardiac function and survival are yet to
be defined. The goal of AMI patient care is to improve
clinical outcome, and the use of an IABP should be
considered when the benefits of counterpulsation are desir-
able; however, this is but one important component in the
overall management of patients with AMI. Clearly, “too
few” patients with cardiogenic shock have IABP support,
and perhaps “too many” are used to support “high-risk”
angiography and angioplasty where the indications are less
clear.
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